Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017146792) COMPOSITIONS OF BIOACTIVE FULVATE FRACTIONS AND USES THEREOF
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

\¥HAT IS CLAIMED IS:

1 . A composition for treatment of a subject in need of cell regeneration comprising an isolated fulvate fraction having an average molecular weight ranging from 80 to 1200 Da, as measured by vapor pressure osmometry.

2. The composition of Claim 1, wherein the isolated fulvate fraction has an average molecular weight ranging from 80 to 350 Da, as measured by vapor pressure osmometry.

3. The composition of any one of Claims 1-2, wherein the isolated fulvate fraction has an average molecular weight ranging from 300 to 320 Da, as measured by vapor pressure osmometry.

4. The composition of any one of Claims 1-3, wherein the isolated fulvate fraction has an average molecular weight of about 308.24 Da, as measured by vapor pressure osmometry.

5. The composition of any one of Claims 1-3, wherein the isolated fulvate fraction has an average molecular weight of 309 Da, as measured by vapor pressure osmometry.

6. The composition of Claim I , wherein the isolated fulvate fraction has an approximate molecular formula of Ci2Hi609.

7. The composition of Claim 1, wherein the isolated fulvate fraction has an approximate molecular formula of C12H16(COOH)(OH)(CO).

8. The composition of any one of Claims 1-7, wherein the composition is formulated as a topical, transdermal, nasal, sublingual, or injectable composition.

9. The composition of any one of Claims 1-8, further comprising a growth factor,

10. The composition of Claim 9, wherein the growth factor is EGF, PDGF, FGF, TGF-a, TGF-β, NGF, EPO, IGF-I, IGF-IL EL- la, IL-Ιβ, IL-2, IL-3, EL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, II,· ! L IL-12, IL-13, IFN-a, IFN-β, IFN-γ, FN Fa. TNF-β, GM-CSF, M-CSF, VEGF, HGF, KGF, or combinations thereof.

11. The composition of any one of Claims 1-10, further comprising one or more bioactive peptide.

12. The composition of Claim 11 , wherein the one or more bioactive peptide is a tigerinin-based peptide.

13. The composition of Claim 11, wherein the one or more bioactive peptide is Syndermin palmitoyl tripeptide-1 amide, Synepin palmitoyl sh-tripeptide-3 amide, Binterin palmitoyl sh-tripeptide-4 amide, Winhibin palmitoyl sh-tripeptide-53 amide, Adiponin palmitoyl sh-tripeptide-1 amide, or combinations thereof.

14. The composition of any one of Claims 1-13, further comprising a pharmaceutically acceptable carrier.

15. A method for relieving, improving, or causing regression of a wound or skin condition in a subject in need thereof, comprising:

selecting a subject in need thereof; and

applying a therapeutically effective amount of a composition comprising a fuivate fraction, the fulvate fraction having an average molecular weight ranging from 80 to 1200 Da as measured by vapor pressure osmometry.

16. The method of Claim 5, wherein the isolated fulvate fraction has an average molecular weight ranging from 80 to 350 Da, as measured by vapor pressure osmometry.

17. The method of any one of Claims 15-16, wherein the isolated fulvate fraction has an average molecular weight ranging from 300 to 320 Da, as measured by vapor pressure osmometry.

18. The method of any one of Claims 15-17, wherein the isolated fulvate fraction has an average molecular weight of about 308.24 Da, as measured by vapor pressure osmometry.

19. The method of any one of Claims 15-18, wherein the isolated fulvate fraction has an average molecular weight of 309 Da, as measured by vapor pressure osmometry.

20. The method of any one of Claims 15-19, wherein the composition further comprises one or more growth factors.

21. The method of Claim 16, wherein the one or more growth factors is EGF, PDGF, FGF, TGF-a, TGF-β, NGF, EPO, IGF-I, IGF-II, IL-la, IL-Ιβ, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-1 1, XL-12, IL-13, IFN-a, IFN-β, IFN-γ, TNFa, TNF-β, GM-CSF, M-CSF, VEGF, HGF, KGF, or combinations thereof.

22. The method of any one of Claims 15-21, wherein the composition further comprises one or more bioactive peptide.

23. The method of Claim 22, wherein the one or more bioactive peptide is a tigerinin-based peptide.

24. The method of Claim 22, wherein the one or more bioactive peptide is Syndermin palmitoyl tripeptide-1 amide, Synepin palmitoyl sh-tripeptide-3 amide, Binterin palmitoyl sh-tripeptide-4 amide, Winhibin palmitoyl sh-tripeptide-53 amide, Adiponin palmitoyl sh-tripeptide-1 amide, or combinations thereof.

25. The method of any one of Claims 15-24, wherein the composition is applied topically, sublingually, transdermally, or nasally.

26. The method of any one of Claims 15-25, wherein the composition is a topical, transdermal, nasal, or sublingual composition.

27. The method of any one of Claims 15-26, wherein the subject suffers from one or more surgical, accidental, or chronic wound or skin condition.

28. The method of Claim 27, wherein the skin condition is rhytide, non-enzymatic glycosylation of the skin, sun damage, smoking damage, fibrosis of the skin, acne aestivalis (Maliorca acne), acne conglobate, acne cosmetica (cosmetic acne), acne fulminans (acute febrile ulcerative acne), acne keioidalis nuchae (acne keloidalis, dermatitis papillaris capillitii, folliculitis keioidalis, folliculitis keloidis nuchae, nuchal keloid acne), adult forehead with scattered red pimples, acne vulgaris, dyshidrosis, acne mechanica, acne medicamentosa, acne miliaris necrotica (acne varioliformis), acne vulgaris, acne with facial edema (solid facial edema), blepharophyma, erythrotelangiectatic rosacea (erythematotelangiectatic rosacea, vascular rosacea), excoriated acne (acne excoriee des jeunes fi ies. Picker's acne), glandular rosacea, gnathophyma, gram-negative rosacea, granulomatous facial dermatitis, adult male with a large, red, bulbous nose, rhinophyma, granulomatous perioral dermatitis, halogen acne, hidradenitis suppurativa (acne inversa, pyoderma fistulans significa, Verneuil's disease), idiopathic facial aseptic granuloma, infantile acne, lupoid rosacea (granulomatous rosacea, micropapular tubercuiid, rosacea-iike tuberculid of Lewandowsky), lupus miliaris disseminatus faciei, metophyma, neonatal acne (acne infantum, acne neonatorum, neonatal cephalic pustulosis), occupational acne, oil acne, ocular rosacea (ophthalmic rosacea, ophthaimorosacea), otophvma, periorificial dermatitis, persistent ederaa of rosacea (chronic upper facial erythematous edema, Morbihan's disease, rosaceous lymphedema), phymatous rosacea, pomade acne, papulopustular rosacea (inflammator' rosacea), perifolliculitis capitis abscedens et suffodiens (dissecting cellulitis of the scalp, dissecting folliculitis, perifolliculitis capitis abscedens et suffodiens of Hoffman), perioral dermatitis, periorbital dermatitis (periocular dermatitis), pyoderma faciale (rosacea fulminans), rhinophyma, rosacea (acne rosacea), rosacea conglobate, synovitis-acne-pustulosis-hyperostosis-osteomyelitis syndrome (SA P! 10 syndrome), steroid rosacea, tar acne, skin cancer (carcinoma and melanoma), tropical acne, plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, nail psoriasis, and psoriatic arthritis.

29. A method for extracting a bioactive poly electrolyte from humified organic matter (HOM), wherein the bioactive polyelectroiyte comprises a fulvate fraction, the method comprising:

providing an aqueous slurry comprising HOM;

applying the aqueous slurry to high pressure column fractionation to obtain fractionated samples;

applying the fractionated samples to molecular sieving; and

isolating a fulvate fraction, the fulvate fraction having an average molecular weight ranging from 80 to 1200 Da as measured by vapor pressure osmometry.

30. The method of Claim 29, wherein the isolated fulvate fraction has an average molecular weight ranging from 80 to 350 Da, as measured by vapor pressure osmometry.

31. The method of any one of Claims 29-30, wherein the isolated fulvate fraction has an average molecular weight ranging from 300 to 320 Da, as measured by vapor pressure osmometry

32. The method of any one of Claims 29-31, wherein the isolated fulvate fraction has an average molecular weight of about 308.24 Da, as measured by vapor pressure osmometry.

33. The method of any one of Claims 29-32, wherein the isolated fulvate fraction has an average molecular weight of 309 Da, as measured by vapor pressure osmometry.

34. The method of any one of Claims 29-33, wherein the isolated fulvate fraction comprises one or more bioactive fragmented peptides.

35. The method of Claim 34, wherein the one or more bioactive fragmented peptide is a tigerinin-based peptide.

36. The method of Claim 34, wherein the one or more bioactive fragmented peptide is Syndermin palmitoyl tripeptide-1 amide, Synepin palmitoyl sh-tripeptide-3 amide, Binterin palmitoyl sh-tripeptide-4 amide, Winhibin palmitoyl sh-tripeptide-53 amide, Adiponin palmitoyl sh-tripeptide-1 amide, or combinations thereof.

37. The method of Claim 29, wherein the isolated fulvate fraction has an approximate molecular formula of C12H160g.

38. The method of Claim 29, wherein the isolated fulvate fraction has an approximate molecular formula of C12H16(COOH)(OH)(CO).